After nearly three years of uncertainty, the FDA has officially reversed its stance on Nicotinamide Mononucleotide (NMN),  the popular anti-aging compound once banned from supplement shelves.

In this episode, we unpack the twists and turns that led to the agency’s dramatic U-turn, the key legal reinterpretation that changed everything, and how relentless industry advocacy forced the FDA’s hand.

From Citizen Petitions to regulatory chaos, discover what really happened behind the scenes, and why this win for NMN could foreshadow the next big battle in dietary supplement regulation.

Tune in to understand the future of NMN, the gaps still left unaddressed, and what this means for innovation in the supplement industry.